Despite the development of novel chemotherapeutic agents and regimens for lung cancer treatment, acquired and inborn drug resistance, including epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance, have been major barriers for chemotherapy. This evidence concerns the gene EGFR and lung cancer.